HIKMA Pharmaceuticals PLC

Remuneration Information • Feb 25, 2022

National Storage Mechanism | Additional information

RNS Number : 8472C

Hikma Pharmaceuticals Plc

25 February 2022

Hikma Pharmaceuticals PLC - EIP Awards

LONDON, 25 February 2022: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)

(LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the following conditional awards under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.

Awards under the EIP were made on 25 February 2022 at a price of 2,219 pence per Ordinary Share (being the average price for the 30-day period prior to 31 December 2021, in accordance with the EIP rules) as follows:

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Said Darwazah
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 34,652
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Said Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Said Darwazah
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 18,420
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Sigurdur Olafsson

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sigurdur Olafsson
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 42,672
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Sigurdur Olafsson

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sigurdur Olafsson
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 23,938
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Mazen Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Mazen Darwazah
2	Reason for the notification
a)	Position/status	Executive Vice Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 27,764
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Mazen Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Mazen Darwazah
2	Reason for the notification
a)	Position/status	Executive Vice Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 15,524
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Bassam Kanaan

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Bassam Kanaan
2	Reason for the notification
a)	Position/status	EVP, Corporate Development and M&A
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 20,588
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Bassam Kanaan

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Bassam Kanaan
2	Reason for the notification
a)	Position/status	EVP, Corporate Development and M&A
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 16,472
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Khalid Nabilsi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Khalid Nabilsi
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 20,643
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Khalid Nabilsi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Khalid Nabilsi
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 17,003
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Riad Mishlawi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Riad Mishlawi
2	Reason for the notification
a)	Position/status	President, Injectables
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 22,099
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Riad Mishlawi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Riad Mishlawi
2	Reason for the notification
a)	Position/status	President, Injectables
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 18,691
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Majda Labadi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Majda Labadi
2	Reason for the notification
a)	Position/status	EVP, Organisational Development
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 13,511
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Majda Labadi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Majda Labadi
2	Reason for the notification
a)	Position/status	EVP, Organisational Development
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 10,778
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Susan Ringdal

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Susan Ringdal
2	Reason for the notification
a)	Position/status	EVP, Strategic Planning and Global Affairs
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 11,072
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Susan Ringdal

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Susan Ringdal
2	Reason for the notification
a)	Position/status	EVP, Strategic Planning and Global Affairs
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 8,851
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Brian Hoffmann

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Brian Hoffmann
2	Reason for the notification
a)	Position/status	President, US Generics
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 14,663
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Brian Hoffmann

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Brian Hoffmann
2	Reason for the notification
a)	Position/status	President, US Generics
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 12,405
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Henriette Nielsen

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Henriette Nielsen
2	Reason for the notification
a)	Position/status	EVP, Business Operations
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 16,610
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Henriette Nielsen

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Henriette Nielsen
2	Reason for the notification
a)	Position/status	EVP, Business Operations
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 13,423
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Shahin Fesharaki

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Shahin Fesharaki
2	Reason for the notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 18,092
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Shahin Fesharaki

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Shahin Fesharaki
2	Reason for the notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 14,424
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Hussein Arkhagha

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Hussein Arkhagha
2	Reason for the notification
a)	Position/status	Chief Counsel
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 10,598
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Hussein Arkhagha

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Hussein Arkhagha
2	Reason for the notification
a)	Position/status	Chief Counsel
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £22.19 Volume(s): 8,675
d)	Aggregated information	N/A
e)	Date of the transaction	25 February 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Peter Speirs

Company Secretary, responsible for releasing this announcement

+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGCGDDXXDDGDU